SAR-445136 is a Gene-Modified Cell Therapy owned by Sangamo Therapeutics, and is involved in 2 clinical trials, which are ongoing.

SAR-445136 is designed to directly regulate sickle cell anemia related genes. BCL11-A modified hematopoietic stem progenitor cells act by direct regulation of disease-related genes and ZFNs to disrupt or correct therapeutically relevant genes. ZFP TFs regulate the cellular copy of the gene and mimic the cell’s natural method of gene regulation turning on or off all of the natural forms of the gene product. The therapeitic candidate allows the body to manufacture red blood cells with an alternate form of hemoglobin unaffected by the mutation that causes the disease.

The revenue for SAR-445136 is expected to reach a total of $319m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the SAR-445136 NPV Report.

SAR-445136 is originated and owned by Sangamo Therapeutics. Sanofi is the other company associated in development or marketing of SAR-445136.

SAR-445136 Overview

SAR-445136 is under development for the treatment of hemoglobinopathies including sickle cell anemia. The therapeutic candidate consists of autologous CD34 hematopoietic stem and progenitor cells transfected with zinc finger nuclease messenger RNAs SB-mRENH1 and SB-mRENH2 and is administered as an intravenous infusion. It is developed based on Zinc Finger Proteins (ZFPs) technology.

Sangamo Therapeutics Overview

Sangamo Therapeutics (Sangamo), formerly Sangamo BioSciences, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Fabry disease, Huntington’s disease, Alzheimer’s disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics, research reagents, pharmaceutical protein production, plant agriculture, cell-line engineering, and production of transgenic animals. Sangamo is headquartered in Brisbane, California, the US.

The company reported revenues of (US Dollars) US$110.7 million for the fiscal year ended December 2021 (FY2021), a decrease of 6.3% over FY2020. The operating loss of the company was US$183.3 million in FY2021, compared to an operating loss of US$129.6 million in FY2020. The net loss of the company was US$178.3 million in FY2021, compared to a net loss of US$121 million in FY2020. The company reported revenues of US$29.4 million for the second quarter ended June 2022, an increase of 4.1% over the previous quarter.

Quick View – SAR-445136

Report Segments
  • Innovator
Drug Name
  • SAR-445136
Administration Pathway
  • Intravenous
Therapeutic Areas
  • Hematological Disorders
Key Companies
Highest Development Stage
  • Phase II


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.